pSivida Corp. (PSDV) Forecasted to Post Q2 2018 Earnings of ($0.14) Per Share
pSivida Corp. (NASDAQ:PSDV) – Research analysts at B. Riley issued their Q2 2018 EPS estimates for pSivida in a report released on Monday. B. Riley analyst A. D’silva expects that the company will earn ($0.14) per share for the quarter. B. Riley has a “Buy” rating and a $5.00 price target on the stock. B. Riley also issued estimates for pSivida’s Q3 2018 earnings at ($0.15) EPS, Q4 2018 earnings at ($0.13) EPS, FY2018 earnings at ($0.56) EPS, FY2019 earnings at ($0.49) EPS, FY2020 earnings at ($0.31) EPS, FY2021 earnings at ($0.14) EPS and FY2022 earnings at $0.00 EPS.
Several other equities research analysts also recently weighed in on PSDV. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of pSivida in a research note on Tuesday, September 12th. Laidlaw started coverage on shares of pSivida in a research note on Wednesday, November 8th. They issued a “buy” rating and a $5.00 target price on the stock. Finally, ValuEngine downgraded shares of pSivida from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. pSivida currently has an average rating of “Buy” and an average target price of $7.57.
pSivida (NASDAQ:PSDV) last released its quarterly earnings results on Tuesday, November 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.15). pSivida had a negative net margin of 226.31% and a negative return on equity of 139.56%. The company had revenue of $0.39 million for the quarter, compared to the consensus estimate of $0.74 million.
A hedge fund recently bought a new stake in pSivida stock. OxFORD Asset Management LLP purchased a new position in pSivida Corp. (NASDAQ:PSDV) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned about 0.18% of pSivida at the end of the most recent quarter. Institutional investors own 9.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/06/psivida-corp-psdv-forecasted-to-post-q2-2018-earnings-of-0-14-per-share.html.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related companies with MarketBeat.com's FREE daily email newsletter.